TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it will be presenting at the Sidoti Virtual Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the company’s RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its first-in-human clinical trial. The presentation will be webcast and an archived recording will be made available in the Investors’ section of the TransCode Therapeutics website.
Related news for (RNAZ)
- TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
- 24/7 Market News Snapshot 08 October, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)
- Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales
- Today’s Top Performers: MoBot’s Market Review 10/08/25 09:00 AM
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company